Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TMED2 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
TMED2 siRNA is a small interfering RNA designed to silence the expression of the Transmembrane p24 trafficking protein 2 (TMED2) gene. TMED2 is a member of the p24 family of proteins, which are involved in the trafficking of proteins between the endoplasmic reticulum and the Golgi apparatus. In the context of oncology, particularly breast cancer, TMED2 has been identified as a potential diagnostic and prognostic biomarker, with high expression levels correlating with poor patient outcomes, increased migratory and invasive capacities of cancer cells, and immune-suppressive tumor environments. Silencing TMED2 via siRNA has been shown in research settings to drastically inhibit the migratory and invasive capacities of breast cancer cell lines such as MDA-MB-231 and HCC1937, suggesting its potential as a therapeutic target for inhibiting tumor progression and metastasis.
- Other names
- siRNA targeting TMED2TMED2 small interfering RNATMED-2 small interfering RNATMED 2 small interfering RNAsiRNA-TMED2siRNA-TMED-2siRNA-TMED 2
02
Targets
Transmembrane emp24 domain-containing protein 2 mRNA
Beyond the preview
Go deeper on TMED2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TMED2 siRNA.